Table 1.

Approved Drugs for RA Treatment

Drug	Structure	Mode of Action	Pivotal Studies
Infliximab	Chimeric monoclonal antibody	Anti TNF inhibitor	ATTRACT Maini 1999
			ASPIRE St Clair 2004
			BEST Yvonne 2007
Etanercept	Fusion protein	Anti TNF inhibitor	ERA Barthon 2000
			COMET Emery 2008
			TEMPO Klareskog 2004
Adalimumab	Human monoclonal antibody	Anti TNF inhibitor	ARMADA Weinblatt 2003
			PREMIER Breedvelt 2006
			OPTIMA Kavanaugh 2013
Certolizumab	Pegylated human monoclonal antibody	Anti TNF inhibitor	RAPID 1 Keystone 2008
			RAPID 2 Smolen 2009
			FAST4WARD Fleischmann 2009
Golimumab	Human monoclonal antibody	Anti TNF inhibitor	GO BEFORE Emery 2009
			GO FORWARD Keystone 2009
			GO AFTER Smolen 2009
Abatacep	Human fusion protein	T Cell co stimulatory inhibition (CD80/CD86)	ABA in MTX RESISTENT PATIENTS Kremer 2006
			ABA in TNF REFRACTORY PATIENTS Genovese 2005
			ACQUIRE Genovese 2011
Tocilizumab	Human monoclonal antibody	AntiIL 6 inhibitor receptor	TOWARD Genovese 2008
			RADIATE Emery 2008
			AMBITION Jones 2010
			ACT-RAY Dougados 2013
Sarillumab	Human monoclonal antibody	AntiIL 6 inhibitor receptor	SARIL-RA-MOBILITY Huizinga 2014
			TARGET Fleischmann 2017
Rituximab	Chimeric monoclonal antibody	B cell depletion (anti CD20)	DANCER Emery 2006
			REFLEX Cohen 2006
Tofacitinib	Small molecule	JAK1 and JAK3 inhibitor	ORAL Start
			ORAL Sync
			ORAL Scan
			ORAL Solo
			ORAL Standard
			ORAL Step
			Oral Strategy
Baricitinib	Small molecule	JAK 1 and JAK 2 inhibitor	RA Begin
			RA Beacon
			RA Bean
			RA Build
			RA Beyond
Upadacitinib	Small molecule	JAK1 inhibitor	SELECT Netx
			SELECT Beyond
			SELECT Monotherapy
			SELECT Early
			SELECT Compare
			SELECT Choice
Filgotinib	Small molecule	JAK1 inhibitor	FINCH 1
			FINCH 2
			FINCH 3
			FINCH 4